Introduction {#s1}
============

Idiopathic interstitial pneumonias (IIPs) are a heterogeneous group of interstitial lung diseases (ILDs) of unknown aetiology. They are classified into distinct disease entities, such as idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (iNSIP) and cryptogenic organising pneumonia (COP) \[[@C1]--[@C4]\]. Accurate diagnosis is essential for estimating prognosis and managing patients with IIPs \[[@C3], [@C5]\], including treatment selection (*e.g.* antifibrotic agents) \[[@C6]--[@C8]\].

Current guidelines emphasise multidisciplinary discussion (MDD) as the gold standard for the diagnosis of IIPs \[[@C2]--[@C4]\]. MDD has been proven to increase interobserver agreement among specialists \[[@C9], [@C10]\]. This indicates that clinicians become more confident of their diagnoses through this discussion. MDD requires close communication between clinicians, radiologists and pathologists. However, several situations preclude MDD, such as a shortage of specialists in each field (*e.g.* thoracic radiologists and pulmonary pathologists), especially within the same institution. Indeed, there are very few institutions worldwide in which MDD diagnosis can be conducted internally. To consult with specialists located in other institutions, the radiological and pathological data (*e.g.* lung biopsy specimens) must be sent separately to each specialist for review, which is very time and cost consuming. Therefore, MDD is not always practical in routine clinical practice.

To address these issues and facilitate MDD in practice, a cloud-based database that integrates clinical, radiological and pathological data of patients with IIPs would be useful. Such a database system enables users (*e.g.* clinicians, radiologists and pathologists) to access and refer to all the data on the web, even if they are in different institutions, areas or countries. This would make it possible to achieve an MDD diagnosis on the internet without assembling specialists in each field in the same place.

The present study was conducted to develop a nationwide cloud-based integrated database with clinical, radiological and pathological data of patients with a diagnosis of IIPs along with a web-based MDD system. To validate the utility of MDD with this system, we performed web-based MDDs with specialists in pulmonology, radiology and pathology for 465 cases of biopsy-proven IIPs. Furthermore, we examined the system\'s diagnostic performance in terms of prognostic discrimination for IIP diagnoses.

Methods {#s2}
=======

Full details are available in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials).

Subjects {#s2a}
--------

39 institutions certified by the Japanese Respiratory Society participated in the present study. The study assessed records of patients diagnosed with IIPs in those institutions who had undergone chest high-resolution computed tomography (HRCT) and surgical lung biopsy (SLB) from April 2009 to March 2014. This retrospective study was approved by the Institutional Review Board of the Hamamatsu University School of Medicine, Hamamatsu, Japan (approval E14-360) and the respective ethics committees of each participating institution.

Collection of clinical, radiological and pathological data {#s2b}
----------------------------------------------------------

A case identification number was allocated to each patient for de-identification purposes. The patients\' clinical and HRCT data within 3 months before the SLB were collected. The clinical data were gathered from the medical records as text data files using commercially available software (FileMaker Platform; [www.filemaker.com](http://www.filemaker.com)). HRCT images were obtained as DICOM (digital imaging and communications in medicine) files. Glass slides of lung biopsy specimens were digitised as whole-slide images using Philips Digital Pathology Solutions (Philips, Amsterdam, The Netherlands). The vital status of the patients was ascertained in October 2017 for survival analysis.

Development of the cloud-based integrated database including clinical, radiological and pathological data {#s2c}
---------------------------------------------------------------------------------------------------------

An outline of the development process is shown in [figure 1](#F1){ref-type="fig"}. The web viewer system and data servers were provided by Esite Healthcare (Tokyo, Japan). The data centre included three servers, *i.e.* one each for clinical, radiological and pathological data. The respective data files were uploaded to each web server separately and the data on the separate servers were interlinked by the respective case identification numbers.

![Schema of the development of the cloud-based integrated database including clinical radiological and pathological data, and web-based multidisciplinary discussion (MDD) using the cloud-based integrated database. HRCT: high-resolution computed tomography. The data centre included three servers, one each for clinical, radiological (HRCT DICOM files) and pathological (whole-slide files) data. Each type of data was uploaded to each web server separately and registered with the appropriate case identification numbers. For web-based MDD, the clinician, radiologist and pathologist referred to the data and evaluated the case based on the information in the database by themselves. They then discussed the case with each other *via* video-conferencing to reach an MDD diagnosis. The final diagnosis was recorded in the cloud-based database. ^\#^: interlinked by the case identification number.](ERJ-02243-2018.01){#F1}

Conducting web-based MDD using the cloud-based integrated database {#s2d}
------------------------------------------------------------------

The database allowed users to access all three types of data for each case through the internet. We devised a model of web-based MDD using the database. A clinician, radiologist and pathologist first accessed the database to examine the case records by themselves, after which they discussed the case *via* video-conferencing (Arcstar Web Conferencing; NTT Communications, Tokyo, Japan) to make an MDD diagnosis ([figure 1](#F1){ref-type="fig"}). Web-based MDD was performed for all cases.

Survival analysis {#s2e}
-----------------

Survival data of the enrolled patients were analysed by both the institutional and MDD diagnoses. The cumulative survival rates were calculated using the Kaplan--Meier method. The log-rank test was employed to compare survival among each IIP diagnostic entity. To control for family-wise error, p-values in multiple comparisons were adjusted using Holm\'s method. Cox proportional hazard models were employed to identify the variables associated with a worse outcome. To compare prognostic discrimination between the institutional and MDD diagnoses, we determined the Harrell C-index for both \[[@C11], [@C12]\]. Statistical analyses were performed using JMP version 9.0 (SAS Institute, Cary, NC, USA) and R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria). A p-value\<0.05 was considered statistically significant.

Results {#s3}
=======

Date collection and development of the cloud-based integrated database {#s3a}
----------------------------------------------------------------------

Clinical, radiological and pathological data of 524 patients were collected from the 39 participating institutions and successfully uploaded to the respective web servers with the appropriate case identification numbers. The data were accessible and available for inspection through the internet in either English or Japanese. A login identifier and password were required to log into the database system. [Supplementary figure E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials) shows representative images of the user interface, including the list of enrolled cases ([supplementary figure E1a and b](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)) and the function of the "display" button. The diagnosis made at each institution and the patient\'s background, laboratory findings and treatment records could easily be retrieved ([supplementary figures E2--E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). The HRCT and lung tissue slide images were accessed by clicking on the "DICOM" and "pathological data" buttons, respectively ([supplementary figure E1c](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). Representative HRCT images are shown in [figure 2a](#F2){ref-type="fig"}. The images could be freely repositioned by the user. The whole-slide images of lung specimens at low and high magnification are shown in [figure 2b](#F2){ref-type="fig"} and c, respectively. The Silverlight plugin (Microsoft, Redmond, WA, USA) was required to view the whole-slide images.

![Chest high-resolution computed tomography (HRCT) and lung biopsy specimen in the cloud-based integrated database. Representative images of a) chest HRCT, and images of a whole slide of a lung biopsy specimen at b) low magnification and c) high magnification.](ERJ-02243-2018.02){#F2}

Patients characteristics and MDD using the cloud-based integrated database {#s3b}
--------------------------------------------------------------------------

Among 524 patients whose data were uploaded to the database, 26 had an institutional diagnosis of an ILD other than IIPs. Of the 498 patients with an institutional diagnosis of IIPs, 33 had insufficient HRCT, pathological and/or prognostic data, and were excluded from analysis. This left 465 cases with an institutional diagnosis of IIPs for analysis in this study ([figure 3](#F3){ref-type="fig"}). Diagnoses made after the MDD were categorised according to the IPF statements \[[@C2]\] and the IIP classification \[[@C3]\] as follows: IPF, iNSIP, COP, desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis-associated ILD (RB-ILD), acute interstitial pneumonia (AIP), lymphoid interstitial pneumonia (LIP), idiopathic pleuroparenchymal fibroelastosis (iPPFE), unclassifiable IIPs and other diseases (not IIPs).

![Study flowchart. IIP: idiopathic interstitial pneumonia; HRCT: high-resolution computed tomography; ILD: interstitial lung disease. Among 524 cases uploaded into the cloud-based integrated database, 26 patients had an institutional diagnosis of an ILD other than IIPs (*e.g.* chronic hypersensitivity pneumonitis or connective tissue disease-related ILD). Of the 498 patients with IIPs as in institutional diagnosis, 33 had insufficient HRCT data, pathology data and/or prognostic data, and were excluded, leaving 465 patients with an institutional diagnosis of IIPs for analysis.](ERJ-02243-2018.03){#F3}

The clinical characteristics of the enrolled patients are presented in [table 1](#TB1){ref-type="table"}. The median patient age was 65 years and 65% were male. Mildly reduced diffusing capacity of the lung for carbon monoxide and elevated Krebs von den Lungen-6 levels were observed. The institutional and MDD diagnoses are shown in [table 2](#TB2){ref-type="table"}. The most prevalent MDD diagnosis was IPF (43%), followed by unclassifiable IIPs (36%). TABLE 1Patient characteristics**Subjects**465**Age years**65 (60--70)**Sex** Male304 (65) Female161 (35)**Never-smoker**175 (38)**FVC % pred**82.0 (69.1--93.9)**FEV~1~ % pred**84.0 (73.0--95.3)***D***~**LCO**~ **% pred**67.1 (53.5--83.0)**KL-6 U·mL^−1^**1054 (633--1731)**SP-D ng·mL^−1^**200 (129--324)Data are presented as n, median (interquartile range) or n (%). FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein D. TABLE 2Institutional and multidisciplinary discussion (MDD) diagnoses**Institutional diagnosisMDD diagnosisIPF**227 (49)200 (43)**iNSIP**99 (21)44 (9)**COP**20 (4)5 (1)**DIP/RB-ILD**16 (3)9 (2)**LIP**5 (1)0**iPPFE**7 (2)18 (4)**Unclassifiable IIPs**91 (20)168 (36)**Other diseases (not IIPs)**021 (5)Data are presented as n (%). IPF: idiopathic pulmonary fibrosis; iNSIP: idiopathic nonspecific interstitial pneumonia; COP: cryptogenic organising pneumonia; DIP: desquamative interstitial pneumonia; RB-ILD: respiratory bronchiolitis-interstitial lung disease; LIP: lymphoid interstitial pneumonia; iPPFE: idiopathic pleuroparenchymal fibroelastosis; IIP: idiopathic interstitial pneumonia.

A chord diagram comparing institutional and MDD diagnoses is shown in [figure 4](#F4){ref-type="fig"}. Overall, the MDD resulted in a change in a diagnosis for 219 patients (47%). As shown in [supplementary figure E5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials), among institutional diagnoses of IPF, 59 cases (26%) were reclassified as unclassifiable IIPs, while 151 (67%) were again diagnosed as IPF by the MDD. The MDD led to a decrease in the diagnosis of iNSIP from 21% to 9%. Among institutional diagnoses of iNSIP, 42 cases (43%) were recategorised as unclassifiable IIPs, 17 (17%) as IPF and three (3%) as connective tissue disease-related ILD (CTD-ILD). Unclassifiable IIPs was more common as an MDD diagnosis (36%) than as an institutional diagnosis (20%). One-third of patients with an MDD diagnosis of unclassifiable IIPs had an institutional diagnosis of IPF, and a quarter each of unclassifiable IIPs and iNSIP ([supplementary figure E6](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). Major causes of unclassifiable IIPs on MDD were "multiple HRCT and/or pathological patterns that may be encountered in patients with IIP", followed by "new entity, or unusual variant of recognised entity" ([supplementary figure E7](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). All 18 patients diagnosed with iPPFE by MDD had abnormalities with an upper or mid-lung field predominance and distinct findings of PPFE on HRCT (bilateral, upper lobe and subpleural dense consolidations with or without pleural thickening \[[@C13]\]). In addition, 12 of the 18 had fibrotic changes in the lower lung fields. No patient was diagnosed as having AIP or LIP by MDD. 21 (5%) patients deemed not to have IIPs were diagnosed with other diseases (chronic hypersensitivity pneumonitis (CHP) n=12, CTD-ILD n=5 and lymphoproliferative disorder n=4). Interstitial pneumonia with autoimmune features (IPAF) was diagnosed in 65 (14%) of the 465 enrolled cases according to IPAF criteria \[[@C14]\]. Of 44 patients with an MDD diagnosis of iNSIP, a substantial proportion (19 patients (43%)) fulfilled IPAF criteria.

![Chord diagram comparing institutional diagnoses (left) and multidisciplinary discussion (MDD) diagnoses (right). IPF: idiopathic pulmonary fibrosis; iNSIP: idiopathic nonspecific interstitial pneumonia; COP: cryptogenic organising pneumonia; DIP: desquamative interstitial pneumonia; RB-ILD: respiratory bronchiolitis-interstitial lung disease; iPPFE: pleuroparenchymal fibroelastosis; LIP: lymphoid interstitial pneumonia.](ERJ-02243-2018.04){#F4}

Survival analysis comparing institutional and MDD diagnoses {#s3c}
-----------------------------------------------------------

Survival curves for the patient cohort subdivided by institutional and MDD diagnoses are shown in [figure 5a](#F5){ref-type="fig"} and b, respectively. Survival analysis demonstrated that patients with IPF had a significantly worse survival than those with non-IPF for both institutional and MDD diagnoses (institutional diagnosis: p\<0.0001; MDD diagnosis: p\<0.0001). To examine differences in prognostic discrimination between the institutional and MDD diagnoses, we performed a log-rank test between adjacent curves (DIP/RB-ILD *versus* COP, COP *versus* iNSIP, iNSIP *versus* unclassifiable IIPs, unclassifiable IIPs *versus* IPF and IPF *versus* iPPFE) and corrected the five p-values using Holm\'s method. Among MDD diagnoses, patients with unclassifiable IIPs had a significantly poorer outcome than those with iNSIP (p=0.034) and those with IPF had a poorer outcome than those with unclassifiable IIPs (p=0.002) ([table 3](#TB3){ref-type="table"}). Notably, patients with iPPFE according to the MDD diagnosis had significantly worse survival than those with IPF (p=0.003) ([table 3](#TB3){ref-type="table"}). The median length of survival and 5-year survival rate were 2.8 years and 23.3%, respectively, for iPPFE. The prognostic significance of MDD diagnoses were evaluated using multivariate Cox proportional hazard regression analysis. Even after adjusting for age and forced vital capacity (percentage predicted), a diagnosis of unclassifiable IIPs was an independent predictor of overall mortality compared with iNSIP ([supplementary table E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). Similarly, IPF was a significant predictor of poor outcome compared with unclassifiable IIPs and iPPFE was a significant predictor of poor outcome compared with IPF ([supplementary table E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). In contrast to the MDD diagnosis, no significant differences were observed in survival between iNSIP and unclassifiable IIPs, unclassifiable IIPs and IPF or IPF and iPPFE based on the institutional diagnosis ([table 3](#TB3){ref-type="table"}). The prognostic discrimination between IIP disease entities was improved by the MDD diagnosis compared with the institutional diagnosis as assessed by the Harrell C-index (0.654 *versus* 0.610, respectively). These results indicate that diagnosis by MDD was superior to institutional diagnosis in separating IIP disease entities prognostically. Survival curves for the patient cohort were subdivided by each type of specialist (pulmonologist, radiologist and pathologist) ([supplementary figure E8](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02243-2018.figures-only#fig-data-supplementary-materials)). The Harrell C-index was 0.614 for pulmonologist diagnosis, 0.614 for radiologist diagnosis and 0.621 for pathologist diagnosis, all of which were lower than the 0.654 index for MDD diagnosis. These findings indicate that MDD with all three specialists pooling their expertise was indispensable for accurate diagnosis of biopsy-proven IIPs.

![Kaplan--Meier survival curves for patients with idiopathic interstitial pneumonias in the cohort subdivided by a) institutional diagnoses and b) multidisciplinary discussion (MDD) diagnoses. DIP: desquamative interstitial pneumonia; RB-ILD: respiratory bronchiolitis-interstitial lung disease; COP: cryptogenic organising pneumonia; iNSIP: idiopathic nonspecific interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; iPPFE: idiopathic pleuroparenchymal fibroelastosis. Lymphoid interstitial pneumonia was excluded because no patient was diagnosed with this disease during the MDD.](ERJ-02243-2018.05){#F5}

###### 

Survival analysis of entities based on institutional or multidisciplinary discussion (MDD) diagnosis

                                            **Institutional diagnosis adjusted p-value^\#^**   **MDD diagnosis adjusted p-value^\#^**
  ---------------------------------------- -------------------------------------------------- ----------------------------------------
  **DIP/RB-ILD *versus* COP**                                      1                                             1
  **COP *versus* iNSIP**                                           1                                             1
  **iNSIP *versus* unclassifiable IIPs**                         0.511                                         0.034
  **Unclassifiable IIPs *versus* IPF**                           0.104                                         0.002
  **IPF *versus* iPPFE**                                         0.450                                         0.003

DIP: desquamative interstitial pneumonia; RB-ILD: respiratory bronchiolitis-interstitial lung disease; COP: cryptogenic organising pneumonia; iNSIP: idiopathic nonspecific interstitial pneumonia; IIP: idiopathic interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; iPPFE: idiopathic pleuroparenchymal fibroelastosis. ^\#^: log-rank, adjusted using Holm\'s method.

Discussion {#s4}
==========

In the present study, we report the development of a nationwide cloud-based integrated database containing clinical, radiological and pathological data of patients with IIPs, based on data from 465 biopsy-proven cases of IIPs. Specialists (pulmonary physicians, radiologists and pathologists) could readily refer to the database on the internet regardless of their physical location. Subsequently, through an online meeting, MDD diagnoses were successfully made by these specialists. Overall, MDD using this system resulted in a change in IIP diagnosis for 219 patients (47%). Notably, the MDD diagnosis yielded better prognostic separation among iNSIP, unclassifiable IIPs, IPF and iPPFE than did the institutional diagnosis. The cloud-based integrated database and the web-based MDD system that we built increases the feasibility of MDD and should result in increased accuracy of diagnosis for patients with IIPs in routine practice.

The most pivotal feature of our cloud-based integrated database is the sharing of clinical, radiological and pathological data anytime and anywhere on the internet. IIPs are a diverse and challenging group of pulmonary diseases with varying prognoses and therapies. MDD is essential in determining the correct diagnosis. The guidelines for IPF \[[@C2], [@C4]\] and for IIPs \[[@C3]\] strongly recommend MDD for this purpose. However, MDD is not feasible in routine clinical practice. To begin with, there are a few radiologists or pathologists specialising in ILD in our country (Japan). Additionally, pulmonary physicians, radiologists and pathologists are often separated by time, geographic location and schedule. Thus, it is difficult to coordinate their timetables to participate in MDD at the same place. Our cloud-based integrated database system resolves these underlying issues in MDD by allowing patient data to be accessed easily by the specialists at their own convenience, after which they can meet by video-conferencing and come to a consensus diagnosis. With the information always available for review on the database, there is no need to gather specialists in one place or to waste time transferring data to other institutions. This cloud-based integrated database system can thus make MDD more practical in the clinic.

Another strength of our cloud-based integrated database is that, in addition to the clinical and radiological data, the pathological data were also available. Web-based access to medical images (*e.g.* HRCT) in the DICOM file format is widely relied upon in modern radiology departments \[[@C15], [@C16]\]. However, few systems are available for accessing pathology images on the web. To engage in MDD on the internet, it is essential that the pathological data can be viewed in the database in the context of the clinical and radiological data. Recent advances have made it possible to create a high-resolution digital image of an entire glass slide using sophisticated digital scanning systems. In the present study, we made whole-slide images of lung tissues from 465 patients with an institutional diagnosis of IIPs and successfully uploaded the images to the cloud-based database. This enabled the specialists to refer to them easily. Our database is the first to incorporate pathological data in the form of whole-slide images along with clinical and radiological data.

In the present study, MDD using our system changed the institutional diagnosis in 219 out of 465 patients (47%). Importantly, this diagnostic reclassification by the MDD led to more distinct prognostic discrimination among the IIP disease entities, including iNSIP, unclassifiable IIPs, IPF and iPPFE, compared with the institutional diagnosis. Interestingly, we found that patients with an MDD diagnosis of iPPFE had a significantly worse outcome than those with IPF. This diagnosis portended a poorer prognosis than DIP/RB-ILD, COP, iNSIP or IPF. iPPFE is characterised by fibrotic thickening of the pleural and subpleural parenchyma predominantly in the upper lobes \[[@C13], [@C17]\], which is a rare form of IIP according to the 2013 American Thoracic Society (ATS)/European Respiratory Society (ERS) IIP guidelines \[[@C3]\]. A few studies have reported that 5-year survival with iPPFE was relatively poor at 30--50% \[[@C18], [@C19]\]. Recently, S[hioya]{.smallcaps} *et al.* \[[@C20]\] retrospectively analysed the characteristics of iPPFE *versus* IPF and found that the outcome of iPPFE was significantly worse than that of IPF. Consistent with these reports, the present study demonstrated a distinctly worse outcome of iPPFE diagnosed by MDD compared with other IIPs, including IPF. While iPPFE was less frequent than IPF in this cohort, its poor prognosis emphasises the importance of accurately diagnosing the specific type of IIPs. The number of patients diagnosed with iPPFE increased from n=7 by institutional diagnosis to n=18 by MDD diagnosis. As iPPFE was first included as an IIP in the 2013 ATS/ERS IIP guidelines \[[@C3]\], patients whose data had been collected before 2013 were likely to have had a different institutional diagnosis. This might partly explain the increased number of MDD iPPFE diagnoses.

In this cohort, 36% of patients had unclassifiable IIPs based on the MDD diagnosis, a relatively higher rate than that in previous studies using MDD \[[@C12], [@C21]--[@C23]\]. As all the patients enrolled in this cohort had undergone SLB, patients with typical clinical and radiological characteristics of IPF were mostly excluded. Thus, our study had some selection bias, which might be a major reason for the high frequency of unclassifiable IIPs. To date, there have been several studies of MDD for diagnosing ILDs; however, these included only small proportions of patients who had undergone SLB. The landmark study of MDD by W[alsh]{.smallcaps} *et al.* \[[@C24]\] included only 22 out of 70 patients (31%) who had had a SLB. J[o]{.smallcaps} *et al.* \[[@C25]\] investigated the impact of MDD on ILD diagnosis in 90 patients, but SLB had been performed for only 16 patients (18%). Thus, the true proportion of unclassified IIP among biopsy-proven IIPs has not been clearly determined. The present study included the largest number of patients with biopsy-proven IIPs reported so far. As cohorts of patients with biopsy-proven IIPs are thought to include a considerable number of cases in which the diagnosis is difficult, we think the proportion of unclassifiable IIPs in such a cohort may be higher than in IIP cohorts that include cases where a biopsy was thought to be unnecessary for diagnosis. Survival with unclassifiable IIPs has been reported to be intermediate between that of IPF and non-IPF \[[@C26]\]. Consistent with that conclusion, we found that survival of unclassifiable IIPs was significantly better than that of IPF, but worse than that of iNSIP. However, unclassifiable IIPs have substantial heterogeneity in their clinical course, response to treatment and outcome \[[@C21], [@C22], [@C27]\]. In addition, there have been wide variations and inconsistencies in the terminology and definitions of unclassifiable IIPs. Further investigation will be required to better understand this group of disorders.

Our cohort did not reflect true populations of patients with IIPs in the real world, because all patients included underwent SLB. Accordingly, the observations of the present study, such as the proportion of each category of IIP diagnosis, may not be applicable to general populations with IIPs. It is of course very important in the clinical setting to differentiate IIPs from ILDs with a known cause, such as CHP or CTD-ILD. Therefore, it will be important to evaluate the performance of MDD diagnosis for a wider range of ILDs. However, the present study, which was funded by the Japanese Ministry of Health, formed a part of the Practical Research Project for Rare Intractable Diseases from the Japan Agency for Medical Research and Development. The definition of rare diseases included IIPs, but excluded other entities such as CHP or CTD-ILD. Our nationwide database for this study was therefore designed to include only patients with IIPs. In this context, the present study clearly indicates that our MDD system performed well in our cohort with good feasibility. The web-based MDD system can easily be applicable to other ILDs. Thus, this system we built could be a promising platform to enable MDD for a variety of ILDs other than IIPs. In the clinical setting, MDD is also performed in cases of ILD without SLB. To further explore this concept, we are currently planning a prospective cohort study including ILDs other than biopsy-proven IIPs. In addition, the digitised clinical, radiological and pathological data of patients with IIPs diagnosed by MDD in our database may be a valuable resource for developing an artificial intelligence-based multimodal diagnostic system for ILD.

There are some limitations to the present study. We successfully carried out web-based MDD using our integrated database. However, a direct data-upload system for the three types of data from each institution has not yet been established. When enrolling new cases of IIPs in the real world, a convenient system for data upload to the web will be necessary. We are now planning to develop such a system. Second, disease behaviour was not considered in making the MDD diagnosis, because the clinical and radiological data considered during the MDD were only current up to the time of the SLB, and no further information (*e.g.* sequential clinical course) was available in the database, which might partly account for a relatively higher incidence of unclassifiable IIPs. Third, MDD was conducted by pulmonologists, radiologists and pathologists. Neither rheumatologists nor occupational medicine specialists participated in MDDs in this study. Fourth, the quality of the history and physical examination available in the database depended on the experience of each patient\'s attending physician in managing ILD and might have varied. Lastly, this was a retrospective cohort study; however, given our findings of the high diagnostic performance and feasibility of our web-based MDD system, a prospective cohort study using this system and including a larger number of patients with ILD is currently being undertaken in Japan.

In conclusion, we developed a nationwide cloud-based integrated database that contains clinical, radiological and pathological data of patients with biopsy-proven IIPs. Using this database, we also built a web-based MDD system that enabled successful conduct of web-based MDD for a large number of patients with IIPs. This database and web-based MDD system make the performance of MDD more feasible in clinical practice, which could increase the accuracy of diagnosis for patients with IIPs.
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